Legend Biotech grants interim CEO 4,908 RSUs

Legend Biotech Corp (LEGN) reported that Interim CEO Alan Bash received a grant of 4,908 restricted share units (RSUs) on August 14, 2026.

Rhea-AI Filing Summary

Legend Biotech Corp (LEGN) reported that Interim CEO Alan Bash received a grant of 4,908 restricted share units (RSUs) on August 14, 2026. These RSUs convert into ordinary shares on settlement, increasing his direct holdings to 35,142 ordinary shares. The RSUs vest in three equal annual installments on July 27, 2027, 2028, and 2029, subject to continued service. Each ordinary share may also be represented by American Depositary Shares, with one ADS equal to two ordinary shares.

Insider Trade Summary

Grant/Award: 4,908 shares

Grant/Award 1 txn

Insider BASH ALAN

Role Interim CEO

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1, F2	4,908	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 35,142 shares (Direct)

Footnotes (2)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. F2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs vest and becomes exercisable on each of July 27, 2027, July 27, 2028, and July 27, 2029, respectively, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

RSUs granted: 4,908 shares Grant price per share: $0.0000 Shares held after transaction: 35,142 shares +2 more

5 metrics

RSUs granted 4,908 shares Restricted share units granted to Interim CEO Alan Bash on August 14, 2026

Grant price per share $0.0000 Per-share price for the RSU award to Alan Bash

Shares held after transaction 35,142 shares Total ordinary shares directly held by Alan Bash after the RSU grant

RSU vesting tranches 1,636 shares per tranche One-third of 4,908 RSUs vesting on each of July 27, 2027, 2028, and 2029

ADS to ordinary share ratio 1 ADS : 2 ordinary shares Relationship between Legend Biotech ADSs and ordinary shares

Key Terms

restricted share units, American Depositary Shares, contingent right

3 terms

restricted share units financial

"Represents restricted share units (the "RSUs"). Each RSU represents a contingent right"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"The Ordinary Shares of the Issuer may be represented by American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

contingent right financial

"Each RSU represents a contingent right to receive one ordinary share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LEGN Interim CEO Alan Bash acquire in this Form 4 filing?

Alan Bash received a grant of 4,908 restricted share units (RSUs), each representing a contingent right to one ordinary share of Legend Biotech upon settlement. This is a compensation-related equity award, not an open-market stock purchase or sale.

How does the RSU vesting schedule work for LEGN’s Interim CEO?

The 4,908 RSUs granted to LEGN Interim CEO Alan Bash vest in three equal tranches. One-third vests on each of July 27, 2027, July 27, 2028, and July 27, 2029, provided he continues to serve Legend Biotech on each vesting date.

What are Alan Bash’s total LEGN share holdings after this RSU grant?

After this RSU award, Alan Bash is reported to directly hold 35,142 ordinary shares of Legend Biotech. This figure includes the effect of the newly granted RSUs as reported, reflecting his updated equity position in the company.

Are LEGN’s ordinary shares related to American Depositary Shares (ADSs)?

Yes. Legend Biotech states that its ordinary shares may be represented by American Depositary Shares (ADSs). Each ADS represents two ordinary shares, providing an alternative way for investors to hold an interest in the company’s equity.

Did LEGN receive any cash from this RSU grant to the Interim CEO?

No cash changed hands in this RSU grant. The RSUs were awarded at a price of $0.0000 per share, reflecting a stock-based compensation grant rather than a cash-funded purchase, and will settle in ordinary shares as they vest over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BASH ALAN

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

77 CORPORATE DRIVE, 4TH FLOOR

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	08/14/2026		A		4,908(2)	A	$0	35,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs vest and becomes exercisable on each of July 27, 2027, July 27, 2028, and July 27, 2029, respectively, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Robert Staloff, Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)